SpringerProtocols: Abstract: Antisense Therapy in Clinical Oncology: Preclinical and Clinical Experiences

Antisense Therapy in Clinical Oncology: Preclinical and Clinical Experiences

By: Ingo Tamm²

Abstract

Full Text

Download PDF (160K)

Nucleic acid molecules have emerged as versatile tools with promising utility as therapeutics for human diseases. The specificity of hybridization of an antisense oligonucleotide (AS-ODN) to the target mRNA makes the antisense strategy attractive for selectively modulating the expression of genes involved in the pathogenesis of malignant or nonmalignant diseases. One antisense drug has been approved for local therapy of cytomegalovirus (CMV) retinitis, and a number of AS-ODNs are currently being tested in clinical trials including oglionucelotides that target bcl-2, protein kinase C-α (PKC-α), and DNA methyltransferase. Clinical studies indicate that AS-ODNs are well tolerated and may have therapeutic activity. In this overview, we summarize therapeutic concepts, clinical studies, and new promising molecular targets to treat human cancer with AS-ODNs.

Affiliation(s): (2) Department of Hematology and Oncology, Humboldt University of Berlin, Charite, Campus Virchow, Berlin, Germany

Book Title: Antisense Therapeutics

Series: Methods in Molecular Medicine | Volume: 106 | Pub. Date: Sep-16-2004 | Page Range: 113-134 | DOI: 10.1385/1-59259-854-4:113

Subject: Cell Biology

References

Download References

1.	Buolamwini, J. K. (1999) Novel anticancer drug discovery. Curr. Opin. Chem. Biol. 3, 500–509.

2.	Clark, R. E. (2000) Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems. Leukemia 14, 347–355.

3.	Baker, B. F. and Monia, B. P. (1999) Novel mechanisms for antisense-mediated regulation of gene expression. Biochim. Biophys. Acta 1489, 3–18.

4.	Crooke, S. T. (1999) Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta 1489, 31–44.

5.	Gewirtz, A. M. (2000). Oligonucleotide therapeutics: a step forward. J. Clin. Oncol. 18, 1809–1811.

6.	Koller, E., Gaarde, W. A., and Monia, B. P. (2000) Elucidating cell signaling mechanisms using antisense technology. Trends Pharmacol. Sci. 21, 142–148.

7.	Khuri, F. R. and Kurie, J. M. (2000) Antisense approaches enter the clinic. Clin. Cancer Res. 6, 1607–1610.

8.	Tamm, I., Dörken, B., and Hartmann, G. (2001) Antisense therapy in oncology: new hope for an old idea? Lancet 358, 489–497.

9.	Waters, J. S., Webb, A., Cunningham, D., et al. (2000) Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-hodgkin’s lymphoma. J. Clin. Oncol. 18, 1812–1823.

10.	Brysch, W., Rifai, A., Tischmeyer, W., and Schlingensiepen, K.-H. (1996) Antisense-medited inhibition of protein synthesis, Antisense Therapeutics (Agrawal, S., ed.), Humana, Totowa, NJ, pp. 159–182

11.	Cotter, F. E. (1999) Antisense therapy of hematologic malignancies. Semin. Hematol. 36, 9–14.

12.	Levin, A. A. (1999) A review of issues in the pharmacokinetics and toxicology of phophorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1489, 69–84.

13.	de Smet, M. D., Meenken, C. J., and van den Horn, G. J. (1999) Fomivirsen-a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul. Immunol. Inflamm. 7, 189–198.

14.	Adams, J. M. and Cory, S. (1998) The bcl-2 protein family: arbiters of cell survival. Science 281, 1322–1326.

15.	Reed, J. C. (1995) Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr. Opin. Oncol. 7, 541–546.

16.	Morris, M. J., Tong, W. P., Cordon-Cardo, C, et al. (2002) Phase I trial of bcl-2 antisense oligonucleotide (G3139) administered by continous intravenous infusion in patients with advanced cancer. Clin. Cancer Res. 8, 679–683.

17.	Cerroni, L., Soyer, H. P., and Kerl, H. (1995) Bcl-2 expression in cutaneous malignant melanoma and benign melanocytic nevi. Am. J. Dermatopathol. 17, 7–11.

18.	Jansen, B., Wacheck, V., Heere-Reess, E., et al. (2000) Chemosensitization of malignant melanoma by BCL2 antisense therapy. Lancet 356, 1728–1733.

19.	Chen, H. X., Marshall, J. L., Trocky, N., et al. (2000) A phase I study of bcl-2 antisense G3139 (GENTA) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Proc. Am. Soc. Clin. Oncol. 19, 178a.

20.	de Bono, J. S., Rowinsky, E. K., Kuhn, J., et al. (2001) Phase I pharmacokinetic (pk) and pharmacodynamic (pd) trial of bcl-2 (Genasense) and docetaxel (D) in hormone refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. 20, 474a.

21.	Tolcher, A. W., Kuhn, J., Basler, J., et al. (2000) A phase I, pharmacokinetic and biologic correlative study of G3139 (Bcl-2 antisense oligonucleotide) and Docetaxel in patients with hormone-refractory prostate cancer (HRPC). Proc. Am. Soc. Clin. Oncol. 19, 527a.

22.	Rudin, C, Otterson, G A., George, C. M., Mauer, A. M., Szeto, L., and Vokes, E. E. (2001a) A phase I/II trial of genasense and paclitaxel in chemorefractory small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 20, 1283a.

23.	Chi, K. N., Gleave, M. E., Klasa, R., et al. (2001) A phase I dose-finding study of combined treatment with an antisense bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastastic hormone-refractory prostate cancer. Clin. Cancer Res. 7, 3920–3927.

24.	Marcucci, G., Bloomfield, C. D., Balcerzak, et al. (2001) Biologic activity of G3139 (Genasense), a bcl-2 antisense (AS), in refractory (REF) or relapsed (REL) acute leukemia (AL). Proc. Am. Soc. Clin. Oncol. 20, 1149a.

25.	Ochoa, L., Kuhn, J., Salinas, R., et al. (2001) A phase I, pharmacokinetic, and biologic correlative study of G3139 and irinotecan (CPT-11) in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 21, 297a.

26.	Bollag, K. and McCormick, F. (1991) Regulators and effectors of ras protein. Annu. Rev. Cell Biol. 7, 601–632.

27.	Bos, J. L. (1989) Ras oncogenes in human cancer: a review. Cancer Res. 49, 4682–4689.

28.	Eckhardt, S. G., Rizzo, J., Sweeney, K. R., et al. (1999) Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J. Clin. Oncol. 17, 1095–1104.

29.	O’Dwyer, P. J., Stevenson, J. P., Gallagher, M., et al. (1999) c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). Clin. Cancer Res. 5, 3977–3982.

30.	Stevenson, J. P., Yao, K. S., Gallagher, M., et al. (1999) Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J. Clin. Oncol. 17, 2227–2236.

31.	Cunningham, C. C, Holmlund, J. T., Schiller, J. H., Geary, R. S., Kwoh, T. J., Dorr, A. & Nemunaitis, J. (2000). A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continous intravenous infusion in patients with advanced cancer. Clin Canc Res 6, 1626–1631.

32.	Rudin, C. M., Holmlund, J., Fleming, G. F., et al. (2001b) Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin. Cancer Res. 7, 1214–1220.

33.	Oza, A. M., Eisenhauer, E., Swenerton, K., et al. (2000) Phase II study of c-raf kinase antisense oligonucleotide ISIS 5132 in patients with recurrent ovarian cancer. Proc. Am. Soc. Clin. Oncol. 19, 530a.

34.	Coudert, B., Anthoney, A., Fiedler, W., et al. (2001) Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer: a European Organization for Research and Treatment of Cancer (EORTC). Eur. J. Cancer 37, 2194–2198.

35.	Cunningham, C. C, Holmlund, J. T., Geary, R. S., et al. (2001) A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer 92, 1265–1271.

36.	Saleh, M., Posey, J., Pleasani, L., et al. (2000) A phase II trial of ISIS 2503, an antisense inhibitor of H-ras, as first line therapy for advanced colorectal carcinoma. Proc. Am. Soc. Clin. Oncol. 19, 320a.

37.	Perez, R. P., Smith, J. W., III, Alberts, S. R., et al. (2001) Phase II trial of ISIS 2503, an antisense inhibitor of H-ras, in patients (pts) with advanced pancreatic carcinoma (ca). Proc. Am. Soc. Clin. Oncol. 20, 628a.

38.	Dang, T., Johnson, D. H., Kelly, K., Rizvi, N., Holmlund, J., and Dorr, A. (2001) Multicenter phase II trial of an antisense inhibitor of H-ras (ISIS-2503) in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20, 1325a.

39.	Yuen, A. R., Halsey, J., Fisher, G. A., et al. (1999) Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin. Cancer Res. 5, 3357–3363.

40.	Mani, S., Rudin, C. M., Kunkel, K., et al. (2002) Phase I clinical and pharmacokinetic study of protein kinase c-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin. Cancer Res. 8, 1042–1048.

41.	Yuen, A., Halsey, J., Fisher, G., et al. (2001) Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 20, 1234a.

42.	Moore, M. R., Saleh, M., Jones, C. M., et al. (2002) Phase II trial of ISIS 3521/LY900003, an antisense inhibitor of PKC-alpha, with docetaxel in non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 21, 297a.

43.	Ritch, P. S., Belt, R., George, S., et al. (2002) Phase I/II trial of ISIS 3521/LY900003, an antinsense inhibitor of PKA-alpha with cisplatin and gemcitabine in advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 21, 309a.

44.	Gradishar, W. J., O’Neill, A., Cobleigh, M., Goldstein, L. J., and Davidson, N. E. (2001) A phase II trial with antisense oligonucleotide ISIS 3521/Cgp 64128a in patients (pts) with metastastic breast cancer (MBC): ECOG trial 3197. Proc. Am. Soc. Clin. Oncol. 20, 171a.

45.	Alavi, J. B., Grossman, S. A., Supko, J., et al. (2000). Efficacy, toxicity, and pharmacology of an antisense oligonucleotide directed against protein kinase C-alpha (ISIS 3521) delivered as a 21 day continous intravenous infusion in patients with recurrent high grade astrocytomas (HGA). Proc. Am. Soc. Clin. Oncol. 19, 167a.

46.	Emmanouilides, C. E., Saleh, A., Laufman, L., et al. (2002) Phase II trial of the efficacy and safety of ISIS 3521/LY900003, an antisense inhibitor of PKC-alpha, in patients with low-grade, non-Hodgkin’s lymphoma. Proc. Am. Soc. Clin. Oncol. 21, 282a.

47.	Luger, S. M., O’Brien, S. G, Ratajczak, J., et al. (2002) Oligonucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. Blood 99, 1150–1158.

48.	Siu, L. L., Gelmon, K. A., Moore, M. J., et al. (2000) A phase I and pharmacokinetik (PK) study of the human DNA methyltransferase (Metase) antisense oligodeoxynucleotide MG98 given as a 21-day continous infusion every 4 weeks. Proc. Am. Soc. Clin. Oncol. 19, 250a.

49.	Wang, H., Cai, Q., Zeng, X., Yu, D., Agrawal, S., and Zhang, R. (1999) Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. Proc. Natl. Acad. Sci. USA 96, 13,989–13,994.

50.	Goel, S., Cho-Chung, Y. S., Nesterova, M. V., et al. (2002) Phase I study monitoring extracellular PKA (ECPKA) levels in a continous intravenous infusion (CIV) with GEM231, a second generation antisense oligonucleotide targeted against PKA RIalpha. Proc. Am. Soc. Clin. Oncol. 21, 1b.

51.	Hau, P., Bogdahn, U., Schulmeyer, F., et al. (2002) TGF-beta2 antisense oligonucleotide AP 12009 administered intratumorally to patients with malignant glioma in a clinical phase I/II dose escalation study: safety and preliminary efficacy data. Proc. Am. Soc. Clin. Oncol. 21, 28a.

52.	Deveraux, Q. and Reed, J. C. (1998) IAP family proteins—suppressors of apoptosis. Genes Dev. 13, 239–252.

53.	Tamm, I., Kornblau, S. M., Segall, H., et al. (2000b) Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res. 6, 1796–1803.

54.	Deveraux, Q., Takahashi, R., Salvesen, G. S., and Reed, J. C. (1997) X-linked IAP is a direct inhibitor of cell death proteases. Nature 388, 300–303.

55.	Takahashi, R., Deveraux, Q., Tamm, et al. (1998) A single BIR domain of XIAP sufficient for inhibiting caspases. J. Biol. Chem. 273(14), 7787–7790.

56.	Dierlamm, J., Baens, M., Wlodarska, I., et al. (1999) The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93, 3601–3609.

57.	Baens, M., Maes, B., Steyls, A., Geboes, K., De Wolf-Peeters, C, and Marynen, P. (1999) Fusion between the apoptosis inhibitor gene API2 and a novel 18q gene MLT, rearranged in the t(11;18)(q21;q21), marks half of the gastro-intestinal MALT-type lymphomas without large cell proliferation. Blood 94, 384a.

58.	Ambrosini, G, Adida, C, and Altieri, D. C. (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med. 3, 917–921.

59.	Tamm, I., Wang, Y., Sausville, E., et al. (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58(23), 5315–5320.

60.	Lu, C. D., Altieri, D. C, and Tanigawa, N. (1998) Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 58, 1808–1812.

61.	Islam, A., Kageyama, H., Takada, N., et al. (2000) High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19, 617–623.

62.	Kasof, G. M. and Gomes, B. C. (2000) Livin, a novel inhibitor-of-apoptosis (IAP) family member. J. Biol. Chem. 276, 3238–3246.

63.	Kawasaki, H., Altieri, D. C, Lu, C. D., Toyoda, M., Tenjo, T., and Tanigawa, N. (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 58, 5071–5074.

64.	Monzo, M., Rosell, R., Felip, E., et al. (1999) A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol. 17(7), 2100–2104.

65.	Sarela, A. I., Macadam, R. C, Farmery, S. M., Markham, A. F., and Guillou, P. J. (2000) Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46, 645–650.

66.	Swana, H. S., Grossman, D., Anthony, J. N., Weiss, R. M., and Altieri, D. C. (1999) Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N. Engl. J. Med. 341(6), 452–453.

67.	Tanaka, K., Iwamoto, S., Gon, G., Nohara, T., Iwamoto, M., and Tanigawa, N. (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res. 6, 127–134.

68.	Adida, C, Berrebi, D., Peuchmaur, M., Reyes-Mugica, M., and Altieri, D. C. (1998) Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351, 882–883.

69.	Li, F., Ackermann, E. J., Bennett, C. F., et al. (1999) Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat. Cell Biol. 1, 461–466.

70.	Suzuki, A., Hayashida, M., Ito, T., et al. (2000) Survivin initiates cell cycle entry by the competitive interaction with Cdk-4/p16INK4a and Cdk2/Cyclin E complex activation. Oncogene 19, 3225–3234.

71.	Li, F., Ambrosini, G., Chu, E. Y., Plescia, J., Tognin, S., Marchisio, P. C, and Altieri, D. C. (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396, 580–584.

72.	Reed, J. C. (1999) Survivin’ cell-separation anxiety. Nat. Cell Biol. 1, 199–200.

73.	Olie, R. A., Simoes-Wüst, A. P., Baumann, B., et al. (2000) A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 6, 2805–2809.

74.	Tamm, I., Höhnemann, D., and Dörken, B. (2000a) Down-regulation of survivin by antisense oligonucleotides in plasmocytoma cells leads to increased apoptosis and sensitivity to chemotherapeutic drugs. Blood 96, 462a.

75.	Jones, S. E. and Jomary, C. (2002) Clusterin. Int. J. Biochem. Cell Biol. 34, 427–431.

76.	Miyake, H., Chi, K. N., and Gleave, M. E. (2000) Antisense TRPM-2 oligodeoxynucleotides chemosensitizes human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin. Cancer Res. 6, 1655–1663.

77.	Zellweger, T., Miyake, H., July, L. V., Akbari, M., Kiyama, S., and Gleave, M. E. (2001) Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 3, 360–367.

78.	Summerton, J. (1999) Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim. Biophys. Acta 1489, 141–158.

Comments (Loading...)

Post comment/View all comments